These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 2849725)

  • 1. Chronic treatment with naltrexone enhances morphine-stimulated dopamine neurotransmission: neurochemical and behavioral evidence.
    Bardo MT; Neisewander JL; Ennis RB
    Neuropharmacology; 1988 Nov; 27(11):1103-9. PubMed ID: 2849725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic naltrexone supersensitizes the reinforcing and locomotor-activating effects of morphine.
    Bardo MT; Neisewander JL
    Pharmacol Biochem Behav; 1987 Oct; 28(2):267-73. PubMed ID: 2825222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic naltrexone increases opiate binding in brain and produces supersensitivity to morphine in the locus coeruleus of the rat.
    Bardo MT; Bhatnagar RK; Gebhart GF
    Brain Res; 1983 Dec; 289(1-2):223-34. PubMed ID: 6318895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of differential rearing environments on morphine-induced behaviors, opioid receptors and dopamine synthesis.
    Bardo MT; Robinet PM; Hammer RF
    Neuropharmacology; 1997 Feb; 36(2):251-9. PubMed ID: 9144663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired supersensitivity to morphine following chronic naltrexone treatment in senescent rats.
    Neisewander JL; Nonneman AJ; Rowlett JK; Bardo MT
    Neurobiol Aging; 1994; 15(1):91-7. PubMed ID: 8159267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic exposure to morphine and naltrexone induces changes in catecholaminergic neurotransmission in rat brain without altering mu-opioid receptor sensitivity.
    De Vries TJ; Tjon Tien Ril GH; Van der Laan JW; Mulder AH; Schoffelmeer AN
    Life Sci; 1993; 52(21):1685-93. PubMed ID: 8388977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in locomotion and dopamine neurotransmission following amphetamine, haloperidol, and exposure to novel environmental stimuli.
    Bardo MT; Bowling SL; Pierce RC
    Psychopharmacology (Berl); 1990; 101(3):338-43. PubMed ID: 2163539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modification of morphine-induced locomotor activity by pertussis toxin: biochemical and behavioral studies in mice.
    Funada M; Suzuki T; Narita M; Misawa M; Nagase H
    Brain Res; 1993 Aug; 619(1-2):163-72. PubMed ID: 8374774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurochemical and functional correlates of naltrexone-induced opiate receptor up-regulation.
    Tempel A; Gardner EL; Zukin RS
    J Pharmacol Exp Ther; 1985 Feb; 232(2):439-44. PubMed ID: 2982011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats.
    Di Chiara G; Imperato A
    J Pharmacol Exp Ther; 1988 Mar; 244(3):1067-80. PubMed ID: 2855239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Augmentation of morphine-induced changes in brain monoamine metabolism after chronic naltrexone treatment.
    Ahtee L; Attila LM; Carlson KR
    J Pharmacol Exp Ther; 1990 Nov; 255(2):803-8. PubMed ID: 2243351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of morphine-induced sensitization by endogenous kappa opioid systems in the rat.
    Spanagel R; Shippenberg TS
    Neurosci Lett; 1993 Apr; 153(2):232-6. PubMed ID: 8392157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of chronic prenatal and postnatal administration of naltrexone in locomotor activity induced by morphine in mice.
    Medina Jiménez M; Luján Estrada M; Rodríguez R
    Arch Med Res; 1997; 28(1):61-5. PubMed ID: 9078589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic d-amphetamine inhibits opioid receptor antagonist-induced supersensitivity.
    Duttaroy A; Billings B; Candido J; Yoburn BC
    Eur J Pharmacol; 1992 Oct; 221(2-3):211-5. PubMed ID: 1330622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic opioid antagonist treatment: assessment of receptor upregulation.
    Yoburn BC; Sierra V; Lutfy K
    Eur J Pharmacol; 1989 Nov; 170(3):193-200. PubMed ID: 2559854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonist-induced up-regulation of the putative epsilon opioid receptor in rat brain: comparison with kappa, mu and delta opioid receptors.
    Giordano AL; Nock B; Cicero TJ
    J Pharmacol Exp Ther; 1990 Nov; 255(2):536-40. PubMed ID: 2173747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitization to repeated morphine injection in the rat: possible involvement of A10 dopamine neurons.
    Kalivas PW; Duffy P
    J Pharmacol Exp Ther; 1987 Apr; 241(1):204-12. PubMed ID: 3572784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Behavioral effects of opioid peptides selective for mu or delta receptors. II. Locomotor activity in nondependent and morphine-dependent rats.
    Locke KW; Holtzman SG
    J Pharmacol Exp Ther; 1986 Sep; 238(3):997-1003. PubMed ID: 3018231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of chronic prenatal morphine treatment of mu-opioid receptor-regulated adenylate cyclase activity and neurotransmitter release in rat brain slices.
    De Vries TJ; Van Vliet BJ; Hogenboom F; Wardeh G; Van der Laan JW; Mulder AH; Schoffelmeer AN
    Eur J Pharmacol; 1991 Oct; 208(2):97-104. PubMed ID: 1686867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opioid modulation of amphetamine-stimulated dopamine release and concentration in rat striatal slices.
    Kolta MG; Bardo MT
    Pharmacol Biochem Behav; 1993 Dec; 46(4):819-25. PubMed ID: 8309961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.